Hims & Hers Health (NYSE:HIMS) Trading 7.5% Higher – What’s Next?

Hims & Hers Health, Inc. (NYSE:HIMS)’s stock price was up 7.5% during trading on Friday . The stock traded as high as $20.32 and last traded at $20.25. Approximately 7,338,671 shares were traded during trading, a decline of 11% from the average daily volume of 8,257,269 shares. The stock had previously closed at $18.83.

Analyst Upgrades and Downgrades

HIMS has been the topic of several recent research reports. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Needham & Company LLC began coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price on the stock. Deutsche Bank Aktiengesellschaft upped their price target on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Truist Financial lifted their price objective on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. Finally, Piper Sandler restated a “neutral” rating and issued a $18.00 target price on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Hims & Hers Health presently has a consensus rating of “Moderate Buy” and an average target price of $20.21.

Hims & Hers Health Price Performance

The firm has a fifty day moving average price of $17.94 and a 200 day moving average price of $18.01. The firm has a market capitalization of $4.38 billion, a PE ratio of 249.91 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 5th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $315.65 million during the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company’s revenue was up 51.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.03) EPS. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,339 shares of the stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $23.16, for a total value of $54,171.24. Following the completion of the sale, the insider now owns 169,935 shares in the company, valued at $3,935,694.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total value of $54,171.24. Following the completion of the sale, the insider now owns 169,935 shares of the company’s stock, valued at approximately $3,935,694.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $16.47, for a total transaction of $3,110,985.36. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $551,777.94. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 858,665 shares of company stock valued at $15,148,890 in the last 90 days. 17.71% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. lifted its stake in shares of Hims & Hers Health by 102.0% in the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company’s stock worth $5,349,000 after buying an additional 146,621 shares during the last quarter. Olympiad Research LP bought a new stake in Hims & Hers Health during the 3rd quarter valued at approximately $262,000. QRG Capital Management Inc. grew its holdings in Hims & Hers Health by 3.9% in the 3rd quarter. QRG Capital Management Inc. now owns 162,029 shares of the company’s stock valued at $2,985,000 after buying an additional 6,077 shares during the last quarter. Robeco Institutional Asset Management B.V. bought a new position in Hims & Hers Health in the 3rd quarter worth approximately $604,000. Finally, Diversify Advisory Services LLC boosted its position in shares of Hims & Hers Health by 14.9% in the third quarter. Diversify Advisory Services LLC now owns 51,828 shares of the company’s stock valued at $955,000 after acquiring an additional 6,706 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.